Comparison
CJC-1295 vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Healing
CAS no.
no data
no data
Molecular weight
3647.3 g/mol
888 g/mol
Half-life
144 h
no data
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACAc-LKKTETQMechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human trial
Animal model
Studies
3
3
of which in humans
2
0
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
3
2